The Interplay between cGMP and Calcium Signaling in Alzheimer’s Disease

Aileen Jehle and Olga Garaschuk *

Abstract: Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger and a key molecule in many important signaling cascades in the body and brain, including phototransduction, olfaction, vasodilation, and functional hyperemia. Additionally, cGMP is involved in long-term potentiation (LTP), a cellular correlate of learning and memory, and recent studies have identified the cGMP-increasing drug Sildenafil as a potential risk modifier in Alzheimer’s disease (AD). AD development is accompanied by a net increase in the expression of nitric oxide (NO) synthases but a decreased activity of soluble guanylate cyclases, so the exact sign and extent of AD-mediated imbalance remain unclear. Moreover, human patients and mouse models of the disease present with entangled deregulation of both cGMP and Ca$^{2+}$ signaling, e.g., causing changes in cGMP-mediated Ca$^{2+}$ release from the intracellular stores as well as Ca$^{2+}$-mediated cGMP production. Still, the mechanisms governing such interplay are poorly understood. Here, we review the recent data on mechanisms underlying the brain cGMP signaling and its interconnection with Ca$^{2+}$ signaling. We also discuss the recent evidence stressing the importance of such interplay for normal brain function as well as in Alzheimer’s disease.

Keywords: cyclic guanosine-3',5'-monophosphate; nitric oxide; neurodegeneration; neuroinflammation; astrocytes; microglia; phosphodiesterase inhibitors

1. Introduction

Cyclic guanosine monophosphate (cGMP) is one of the ubiquitous second messengers of the body and brain. It targets a manifold of downstream pathways, thus eliciting a broad variety of cellular/tissue effects. The role of cGMP has been extensively studied in the periphery, where it has important physiological functions in the vasculature, heart, pulmonary arteries, and gastrointestinal tract [1]. The dysfunction of the aforementioned pathways (e.g., in the cardiovascular domain) is common and the development of drugs, targeting these pathways, has substantial therapeutic implications. The most known are phosphodiesterase (PDE) inhibitors (e.g., PDE5 inhibitor Sildenafil), used in erectile dysfunction [2]. In the brain, cGMP is involved in signal transduction in the retina as well as synaptic plasticity, learning and memory formation, activity-dependent hyperemia, and inflammation [3,4]. Therefore, it has gained attention as a possible druggable target for treating neurodegenerative diseases.

In neuro-glial brain networks, the production of cGMP is modulated in an activity-dependent manner, with increases in synaptic transmission as well as second messenger-mediated rises in the cytosolic free Ca$^{2+}$ concentration ([Ca$^{2+}$]$_i$) enhancing the production of cGMP [5–7]. Both neuronal activity and Ca$^{2+}$ signaling are affected in Alzheimer’s disease (AD) patients or mouse models of the disease [7–9]. In fact, AD patients are known to have an increased incidence of epileptic seizures, which is independent of the disease stage and highest in cases with early disease onset [7,10–12]. The vicinity of amyloid plaque deposits, studied in animal models of the disease, is known for its profound neuronal, astrocytic,
and microglial hyperactivity [8,10,12]. AD is the most common form of dementia, and it is expected that the number of AD cases will rise significantly in the years to come due to the aging of the Western population, consequences of the COVID-19 pandemic, and profound inflammation/brain traumata obtained during war [13–15], making this disease a major concern for modern society.

The cGMP signaling pathway is reportedly affected during the early stages of AD [16], making it an interesting target for developing new treatment strategies. In this review, we summarize the physiological roles of the cGMP signaling pathway in different constituents of the neuro-glial brain network, its interconnection with Ca\(^{2+}\) signaling, its implications in AD, and the current attempts in developing new AD therapies targeting the cGMP signaling pathway.

2. cGMP Toolkit in the Brain

There are two main pathways for cGMP production (Figure 1). The first pathway is mediated by NO. This short-lived free radical molecule is mainly produced through nitric oxide synthases (NOS). Like other tissues, the brain contains two types of the constitutively expressed NOS (neuronal (nNOS) and endothelial (eNOS)) as well as the inducible NOS (iNOS), whose expression is triggered by different stimuli. The nNOS is widely expressed throughout the brain and is abundant in neurons, but it is also found in other brain cells such as astrocytes and endothelial cells. eNOS is most commonly expressed in endothelial cells [17], but also in blood vessel-associated astrocytes as well as in the layer II–IV cortical neurons [18,19]. The activity of both types of constitutively expressed NOS is regulated by Ca\(^{2+}\) and calmodulin [20,21]. This mechanism of activation enables a fast and transient increase in the intracellular NO concentration in response to cells’ activity. In contrast to constitutively expressed NOS isoforms, the expression of iNOS is triggered. This form of NOS is part of the immune response machinery and therefore is mainly found in astrocytes and microglia [22]. To a smaller degree, it is also expressed in neurons and endothelial cells of the blood–brain barrier (BBB) [23]. The main stimuli inducing iNOS activity are tumor necrosis factor-alpha (TNF-\(\alpha\)), interleukin-1\(\beta\) (IL-1\(\beta\)), interferon-gamma (IFN-\(\gamma\)), lipopolysaccharide (LPS), and double-strand RNA (dsRNA) [22,24,25]. The subsequent NO production is primarily regulated at the transcriptional level through binding sites for the nuclear factor\(\kappa\)B (NF-\(\kappa\)B) and the phosphorylated cyclic adenosin monophosphate (cAMP) response element-binding protein (pCREB) in the promoter region of the iNOS gene [26,27]. Once the expression of iNOS is triggered, it generates NO over a prolonged period of time. One factor controlling the expression of iNOS via NF-\(\kappa\)B is the nuclear factor erythroid 2-related factor 2 (Nrf2). This transcription factor can be activated by NO [28,29] and causes, among others, the expression of heme oxygenase 1. This protein is known to inhibit NF-\(\kappa\)B, thus causing a NO-coupled reduction in iNOS expression in case of inflammation (Figure 1).

As a gaseous molecule, NO can induce both an intracellular as well as an intercellular response by triggering the production of cGMP by the soluble guanylate cyclases (NO-GCs). Depending on the cell type, the NO-GC is predominantly cytosolic, or predominantly membrane-associated, as, for example, in neurons [30]. The enzyme contains two subunits, a longer \(\beta\)-subunit and a shorter \(\alpha\)-subunit, together forming an \(\alpha/\beta\)-heterodimer, which is required for catalytic activity [31]. There are two subtypes of NO-GC. Both subtypes contain four structures: a coiled-coil domain, a Per-Arnt-Sim (PAS) domain, the heme-nitric-oxide oxygen binding (H-NOX) domain, and the catalytic domain (CAT) [32–35]. NO binds to the H-NOX domain, leading to a conformational change, allowing the catalytic domain to produce cGMP from GTP [36]. NO-GC-1, formed by an \(\alpha1\beta1\)-heterodimer, is widely expressed throughout the organism, whereas the NO-GC-2 (\(\alpha2\beta1\)-heterodimer) is strongly expressed in the CNS [37].
The second pathway of cGMP production is triggered by the activation of natriuretic peptide receptors (NPRs). Three types of these receptors, all having an extracellular binding domain for natriuretic peptides (NPs), are known to date. Two subtypes have an intracellular guanylate cyclase domain [38]. These are the NPR-A (also called particulate NPR1 or pGC-A), activated by atrial natriuretic peptide (ANP), and brain-type natriuretic peptide (BNP) as well as the NPR-B (also called NPR2 or pGC-B) activated by C-type natriuretic peptide (CNP). NPR-C (also called NPR-3) has no intracellular catalytic domain and no enzymatic activity. Its main function is the clearance of NP from the extracellular fluid [39]. There is also evidence that NPR-C can activate G-proteins, which inhibit adenylyl cyclase activity.

NPs are expressed in many tissues including the brain, with different distributions in different brain areas. NPR-B is ubiquitously expressed in neurons and glial cells throughout all brain areas (gene name npr2, available from www.proteinatlas.org, accessed on 23 March 2022) [40]. NPR-A has very low expression within the brain, but it can be found within endothelial cells (gene name npr1, available from www.proteinatlas.org, accessed on 23 March 2022) [40]. ANP and BNP are mostly expressed in muscle tissue, but in low concentrations; they can also be found in the CNS [41–44]. Although proteomic profiling shows very low NPR-A in the brain, there is some evidence for ANP signaling via NPR-A in astrocytes [45]. The third natriuretic peptide CNP has the strongest expression in the brain (10 times higher than that for ANP or BNP [46]). The expression is widespread throughout the different brain regions and is mainly localized to inhibitory interneurons and glial cells.
(gene name nppc, available from www.proteinatlas.org, accessed on 23 March 2022) [40], suggesting that CNP signaling is the major NP signaling type in the brain.

cGMP can modulate the activity of three different proteins (Figure 1). One of these downstream targets is the cGK (protein kinase G), a member of the family of serine/threonine protein kinases. Generally, there are two different cGKs, encoded by the prkg1 and the prkg2 genes. cGK-I has two splice variants, cGK-Iα and cGK-Iβ. All cGK isoforms are widely distributed throughout the brain, with different distributions in different brain areas [47–49]. Upon cGMP binding, the phosphotransferase activity of cGK is increased, leading to the phosphorylation of downstream targets [50,51]. cGK has a regulatory domain that can be autophosphorylated [52], leading to activation of the enzyme [53]. Phosphorylation by cGK has been implicated in many brain functions, including anxiety and fear behavior [54,55], generation of the circadian rhythm [55,56], and long-term potentiation [57,58].

The cyclic nucleotide-gated ion channels (CNGCs) are the second target of cGMP. Although part of the voltage-gated ion channel superfamily, these channels possess functional properties of ligand-gated ion channels. They have an intracellular ligand-binding domain, which can be accessed by both cGMP and cAMP, leading to an influx of Na⁺ and Ca²⁺ and an efflux of K⁺ [59]. CNGCs were first found in cone photoreceptors [60], but further studies have identified CNCGs in many different tissues, including the brain, where the CNGC activation by cGMP modulates glutamatergic signaling [61].

The third class of proteins affected by cGMP are phosphodiesterases (PDEs; Figure 1). These enzymes are responsible for the degradation of cyclic nucleotides. To date, 11 types of PDEs have been identified. Some PDEs are specific for cAMP (PDE4, 7, and 8) and others for cGMP (PDE5, 6, and 9). The rest of the PDEs are dual-substrate PDEs, able to hydrolyze both cAMP and cGMP. Most PDEs can be found in the CNS, with different expression levels in different brain regions [62,63]. The cGMP-specific PDE6 is only expressed in the retina, whereas PDE5 and PDE9 are commonly found in the CNS. cGMP itself can control some of the PDE activity (Figure 1). For example, a low concentration of cGMP is able to decrease PDE3 activity, allowing for an increase in cAMP concentration, whereas a higher cGMP concentration leads to an increase in PDE2 activity, reducing cAMP concentration, and to a smaller extent, also the cGMP concentration [64]. PDE5 activity is also regulated by cGMP through cGK-I phosphorylation [65]. Interestingly, the cGMP-specific PDE5 and PDE9 seem to control different subcellular pools of cGMP. PDE5 mainly controls the cGMP pool formed through NO/NO-GC activation, whereas PDE9 controls the NP/NPR pool of cGMP [66].

The NO/cGMP/cGK pathway has autoregulatory capabilities. As a phosphokinase, cGK can regulate the activity of other enzymes. Some of the targets for cGK belong to the NO/cGMP/cGK pathway. For example, cGK can decrease the activity of NO-GC, serving as a negative feedback mechanism for cGMP production [67,68]. cGK also changes PDE5 activity (Figure 1). By phosphorylating this enzyme, the affinity for cGMP increases, leading to faster degradation of cGMP and therefore a faster termination of the cGMP-mediated signaling [67].

Taken together, brain cells possess a complex and versatile cGMP toolkit, capable of monitoring changes in neural network activity as well as a release of multiple modulatory substances (Figure 1). Via numerous, and in many instances, cell type-specific (see below), interactions between different components within and outside of the NO/cGMP/cGK pathway, the cGMP signaling is likely to play an important, although not yet completely understood, role in brain function.

3. Cell Type Specificity of the cGMP Pathway

The NO/cGMP/cGK pathway has been implicated in many processes within the brain, such as modulation of synaptic transmission, neuroprotection, and immune response. In these processes, cGMP can have a beneficial or a detrimental effect, depending on its concentration and the cell type under study. Since the possible effects of cGMP are diverse,
it is worth taking a closer look at cell type-specific cGMP signaling pathways in the most important cell types of the brain (Figure 2).

Figure 2. The functional roles of the cGMP signaling pathways in neurons, astrocytes, microglia, endothelial cells, and pericytes (see text for detailed description). AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; GluA1: ionotropic glutamate receptor of AMPA type, subunit 1; CREB: cAMP response element-binding protein; GFAP: glial fibrillary acidic protein; IL6: interleukin 6; LPS: lipopolysaccharide; NF-κB: nuclear factor kappa B; NMDA-R: N-methyl-D-aspartate-receptor; RhoA: Ras homolog family member A; ICAM: intercellular adhesion molecule; VCAM: vascular cell adhesion molecule; all other abbreviations are explained in the figure legend for Figure 1.

3.1. cGMP Signaling in Neurons

NOS, NO-GC, and cGK can be found in neuronal somata, dendrites, and in dendritic spines, pointing toward the important role of the NO/cGMP/cGK pathway in synaptic transmission. A well-known role of cGMP is its involvement in the long-term potentiation of synaptic transmission, a key process for learning and memory formation. An increase in cGMP production was observed in response to the activation of glutamatergic N-methyl-D-aspartate (NMDA), cholinergic and dopaminergic receptors [69–72]. At glutamatergic synapses, both nNOS and NO-GC-2 were shown to bind to the PDZ domain of post synaptic density protein 95 (PSD-95), a major scaffolding molecule enriched at glutamatergic synapses [30,73]. This proximity allows for the fast and specific relay of the information from the level of pre-/postsynaptic activity to the NO/cGMP/cGK pathway. Strong neuronal activation and hereby induced NMDA receptor-mediated Ca^{2+}-influx lead to the activation of nNOS [5,6], an increase in the intracellular NO concentration, activation of NO-GC, production of cGMP, and activation of cGK, which can phosphorylate downstream targets. In conditions of the LTP induction, there are two main functions of cGK (Figure 2). Activated cGK-I can translocate to the nucleus, where it phosphorylates CREB,
thus inducing the transcription of LTP-relevant genes [74–76]. Furthermore, cGK-II can phosphorylate GluA1, an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit, leading to more AMPA receptors being included in the postsynaptic density [77,78].

Next to the postsynaptic function, the pathway is also involved in the presynaptic part of LTP (Figure 2). nNOS and NO-GC can be found in both pre- and postsynaptic structures. NO-GC is mostly found presynaptically, whereas nNOS is mainly found in the postsynaptic density [79]. Interestingly, the presynaptic structures containing NO-GC often oppose nNOS-containing postsynaptic structures [79]. The role of NO as a retrograde messenger between pre- and postsynaptic structures has been well established [80–82]. It is either produced by NMDA receptor-coupled nNOS, or by eNOS [83,84], which can be, for example, found in postsynaptic structures of cortical neurons [85]. Two NO-GC isoforms are expressed in the CNS. NO-GC-1 is mostly found in presynaptic structures, whereas NO-GC-2 is more commonly found postsynaptically [79,83]. Consistently, the NO-GC-1 stimulation was shown to be involved in the NO/cGMP-mediated increase in the presynaptic glutamate release in hippocampal CA1 neurons [83]. Increased vesicle release is likely induced by activation of hyperpolarization-activated CNGCs (Figure 2) [83]. During prolonged synaptic stimulation, the activation of cGK is needed for vesicle recycling, most likely by increasing the amount of phosphatidylinositol-4,5-bisphosphate (PIP2, Figure 2) [86–88].

cGMP is also involved in structural plasticity through the activation of cGK, and the cGK-mediated phosphorylation of downstream effectors, such as vasodilator-stimulated phosphoprotein (VASP) and the Ras homologue-GTPase A (RhoA) [89]. Depending on their phosphorylation status, both proteins can alter actin remodeling. VASP is an actin-binding protein, inducing actin assembly and thus influencing the density, size, and morphology of synapses [90]. It was shown that spine development is positively influenced by VASP through NO/NO-GC signaling [91]. RhoA is another protein influencing actin remodeling. RhoA signaling is associated with dendrite retraction and inhibition of synapse formation [92]. Activation of the NO/cGMP/cGK signaling pathway can induce RhoA-mediated loss of synapses [93]. Therefore, cGMP signaling can have both a beneficial and a detrimental effect on spine stability.

Taken together, cGMP signaling is involved in several aspects of LTP. It can influence early LTP through presynaptic modulation of vesicle release and affect late-phase LTP through the induction of gene expression and synaptic stability. These processes are all tightly regulated, and their imbalance can have a detrimental effect on synaptic signaling.

3.2. cGMP Signaling in Astrocytes

Astrocytes play a key role in brain homeostasis, including buffering of extracellular K+ and pH, regulation of synaptic transmission as well as water transport, maintenance of the blood-brain barrier, and providing energy substrates to neurons. Additionally, they are part of the immune defense of the brain.

Astrocytes express many elements of the cGMP signaling pathway, including all three NOS isoforms (Figure 2). However, nNOS is found in much lower concentrations in astrocytes than in neurons and at a different subcellular location. In neurons, nNOS is coupled to NMDA receptors via the PDZ-binding domain (see above), whereas in astrocytes, nNOS is mostly found in the cytosol [94]. eNOS, the second type of Ca2+-activated NOS, is mainly found in blood vessel-associated astrocytes [18,19]. The expression of iNOS, the inducible isoform of the NO synthase, can be triggered through several stimuli, including dsRNA, TNF-α, and proinflammatory cytokines [95–97]. iNOS expression is prominent in astrocytes and microglia, where it is induced by danger-associated signals or damage of the brain parenchyma. These extracellular pathogenic stimuli activate NF-κB, which in turn activates the NO/cGMP/cGK pathway by inducing iNOS expression. Through the upregulated iNOS expression, a large amount of NO molecules is produced, activating the astrocytic NO-GC and leading to the production of cGMP. An increase in cGMP upon iNOS
expression has been shown in cell culture and acute brain slices [45–98]. The produced cGMP then activates cGK, thus activating the respective effector pathways.

Astrogliosis is a part of the immune response associated with a change in astrocytic morphology towards a hypertrophic state, a translocation towards the site of the immune challenge, and a change in gene expression. One important hallmark of astrocyte reactivity is an increase in the expression of the glial fibrillary acidic protein (GFAP). It was shown that an increase in cGMP leads to an increase in GFAP expression and that the induction of GFAP expression is dependent on NO/cGMP/cGK signaling [99–102]. Furthermore, cGMP can induce a change in astrocytic morphology via GFAP and actin remodeling. This process requires RhoA-GTPase to be phosphorylated, and thus inhibited, by cGK [101]. Although this is the most commonly described role of cGMP in astrocytes, there are also studies showing a decrease in GFAP expression upon administration of NO-GC stimulators [103]. Next to the signaling via NO, this pathway can also be triggered by ANP, since astrocytes contain pGC-A [45].

### 3.3. cGMP Signaling in Microglia

As the resident immune cells, microglia are the main mediators of inflammatory response in the brain. As in astrocytes, cGMP signaling is involved in microglial response to tissue damage or challenge with pathogens. Nevertheless, astrocytes and microglia show some differences in the cGMP signaling. First of all, microglia do not contain the Ca\(^{2+}\)-dependent NOS, but the expression of iNOS can be induced by multiple cytokines, LPS, amyloids, or viral challenges [25,104–106]. The NO-activated NO-GC has not been detected in microglia; thus, in these cells, NO seems to serve a different function [25,107,108], for example, by attenuating the generation of reactive oxygen species and respiratory burst in a cGMP-independent manner [109]. In peripheral macrophages, activation of peroxisome proliferator-activated receptor γ by NO attenuates respiratory bursts [110]; whether a similar effect is present in microglia is not known.

As a diffusible molecule, NO has a second/retrograde messenger function in both intra- and intercellular signaling. For example, the NO produced in microglia during inflammation induces the expression of Nrf2 as well as heme-oxygenase 1 (see above), and thereby activates a feedback loop inhibiting the iNOS expression in an autocrine as well as paracrine (e.g., in the neighboring astroglia) way. Some studies revealed a correlation between an increase in microglial iNOS, neuronal cGMP, and neuronal apoptosis [111,112], while others showed that increased NO concentration is neuroprotective [113]. One theory explaining these different results suggests that the duration of exposure to the increased NO/cGMP/cGK signaling is relevant for neurotoxicity. Accordingly, transient exposure would have antiapoptotic and sustained exposure proapoptotic effects [111].

As microglia do not contain NO-GC (see above), they likely produce cGMP in a NO-independent but ANP-dependent manner [108]. Indeed, stimulation of microglial cells with ANP reduces LPS-induced microglial activation [114]. Nevertheless, several publications revealed microglial sensitivity to the manipulations of the NO-GC signaling [103,115]. For example, in the scratch wound in vitro models, as well as under acute spinal cord injury conditions in vivo, the application of the NO-GC inhibitor ODQ significantly reduced microglial motility [116–119].

Whether the cGMP signaling has a pro- or anti-inflammatory effect in microglia is still debated. In the case of traumatic brain injury, the application of a PDE inhibitor leads to a reduction in the number of amoeboid microglia around the site of injury, together with a decrease in the expression of the ionized Ca\(^{2+}\)-binding adaptor molecule 1 (Iba-1) and Cd11b [102]. It was shown that cGMP can reduce the inflammatory response to LPS stimulation, as shown by the reduced expression of proinflammatory genes [103,114]. On the other hand, there are also reports of increased Iba-1, iNOS, Cd11, MHC class II, and proinflammatory cytokine expression (i.e., increased inflammation) upon cGMP accumulation [99,120,121]. The inflammation-induced deramification of microglia does not seem to be affected by cGMP signaling [122].
Although many studies on the role of cGMP in microglia have been conducted, the results remain controversial, suggesting a complex and context-dependent mechanism, which needs further investigation.

3.4. cGMP Signaling in Endothelial Cells and Pericytes

Endothelial cells are part of the blood–brain barrier (BBB). The NO/cGMP/cGK pathway in these cells is involved in cell motility, migration, proliferation, processes important for vessel integrity, endothelial barrier function, and angiogenesis [123]. All relevant proteins of the NO/cGMP/cGK pathway can be found in endothelial cells (Figure 2) [124]. For example, it was shown that CNP-pGC/cGMP signaling causes vasodilation in cerebral arterioles [125] and modulates the BBB permeability via a reduced expression of zonula occludens-1 protein forming tight junctions [126]. In the case of pathogen challenge, however, the signaling seems to work differently. Activated endothelial cells express the intercellular adhesion molecule (ICAM) and the vascular cell adhesion molecule (VCAM), which allow leukocytes to enter the brain parenchyma [127]. The cGMP pathway down-regulates the expression of both proteins, leading to decreased immigration of peripheral immune cells (T-cells) into the brain [99]. In addition, the activation of the NO/cGMP/cGK pathway counteracts the inflammatory cytokine-induced increase in the BBB permeability, likely by affecting F-actin remodeling [128,129].

Pericytes are contractile cells on capillaries, which control cerebral blood flow and contribute to the BBB [130]. NO, acting on pericytes in a cGMP-dependent manner, can induce vessel dilation [131] since these cells contain both sGC [132] and cGK (Figure 2) [133]. The NO/cGMP/cGK-mediated dilation of blood vessels is caused by the relaxation of vascular smooth muscle cells either directly or via endothelial cells and pericytes [134,135]. One of the factors interconnecting endothelial cells and pericytes is the vasoconstrictive endothelin-1 (ET1) [136]. There is a strong interconnection between NO and ET1 signaling [137]. NO can inhibit ET1 release and ET1 can inhibit NO production [137,138]. Together, this allows for tight regulation of vasodilation.

4. Interplay between Calcium and cGMP Signaling

Calcium is the most abundant second messenger of the body and brain and an important mediator in a variety of cellular processes. Under physiological conditions, the \([Ca^{2+}]_i\) is low due to the constant removal of Ca\(^{2+}\) from the cytosol. The extrusion mechanisms include the plasma membrane Ca\(^{2+}\)-ATPase (PMCA pump), the transmembrane Na\(^+\)/Ca\(^{2+}\) exchanger, as well as the sarco-/endoplasmatic reticulum Ca\(^{2+}\)-ATPase (SERCA pump), mediating the reuptake of Ca\(^{2+}\) into the endoplasmatic reticulum (ER). The Ca\(^{2+}\) and the cGMP signaling pathways are interconnected. The most obvious link is the Ca\(^{2+}\)-dependent NO production by nNOS and eNOS described above. Both constitutively active forms of NOS have a binding site for calmodulin. For nNOS, it was shown that at low [Ca\(^{2+}\)]_i, calmodulin (CaM) is either free or pre-bound to nNOS with its C-terminus. Upon an increase in [Ca\(^{2+}\)]_i, also the N-terminus of CaM is binding to nNOS, enabling the activation of this enzyme. Upon sequestration of intracellular Ca\(^{2+}\), Ca\(^{2+}\) dissociation from the N-terminus of CaM likely causes nNOS deactivation [6]. Besides the direct Ca\(^{2+}\)/CaM sensitivity of the nNOS activation process, there is also an additional Ca\(^{2+}\)-dependent regulatory mechanism, mediated by the Ca\(^{2+}\)/calmodulin-dependent kinase II (CaMKII) [139]. Phosphorylation of nNOS by the CaMKII attenuates the catalytic activity of nNOS and leads to a reduction in NO production [139,140]. Additionally, when Ca\(^{2+}\) and cGMP pathways are activated simultaneously, they can have a synergistic effect on the induction of c-Fos expression [141,142].

It must be taken into account that cGMP signaling is strongly compartmentalized. The site of production, either in the cytosol by NO-GC or at the membrane by pGC, is one of the factors generating a localized cGMP pool. Secondly, the spread of cGMP throughout the cell is limited by PDEs. PDEs themselves show distinct subcellular localization and thus, a differential control of the specific cGMP pools is possible (reviewed in [143]).
Similarly, the interplay between the Ca\(^{2+}\) and cGMP signaling differs depending on the exact subcellular location. It was shown, for example, that cGMP produced in the cytosol enhances the SERCA-mediated reuptake of Ca\(^{2+}\) into the ER, thus reducing the [Ca\(^{2+}\)]\(_i\), but downregulates the efflux of Ca\(^{2+}\) via PMCA [144]. The pGC signaling via CNP most likely stimulates L-type Ca\(^{2+}\) channels, thus increasing the influx of Ca\(^{2+}\) via the plasma membrane [145]. Additionally, cGMP was shown to control the release of Ca\(^{2+}\) from the ER, mediated by ryanodine receptors (RyR). In hippocampal LTP, for example, NO-mediated activation of the NO/cGMP/cGK pathway likely also activates ADP-ribosyl cyclase, stimulating the production of cyclic ADP-ribose, which acts synergistically with cytosolic Ca\(^{2+}\) to trigger RyR-mediated Ca\(^{2+}\) release from the intracellular Ca\(^{2+}\) stores [146].

Ca\(^{2+}\) signaling is an important mediator of neuro-glial interaction. The release of glutamate from neurons can trigger intercellular Ca\(^{2+}\) waves in astrocytes, thus altering synaptic transmission between neurons [147]. It was shown that in astrocytes, RyR-mediated Ca\(^{2+}\) release from the ER is potentiated by the activation of the NO/cGMP/cGK signaling pathway [148]. Such interplay between Ca\(^{2+}\) and NO supports the generation and propagation of both intra- and intercellular Ca\(^{2+}\) waves, as rises in [Ca\(^{2+}\)]\(_i\), trigger the generation of NO by constitutively active NO\(_\text{Ss}\), and NO, as a freely diffusible molecule, supports RyR-mediated Ca\(^{2+}\) release in further cells/subcellular compartments. Finally, rises in [Ca\(^{2+}\)]\(_i\) were shown to release ANP from astrocytes by means of Ca\(^{2+}\)-dependent exocytosis [149]. ANP, in turn, might contribute to several key regulatory processes within the neuro-glial network, including the activity-dependent regulation of cerebral blood flow or activation of microglia [150,151] (Figure 2).

Taken together, the interplay between the Ca\(^{2+}\) and cGMP signaling forms a closed loop, important for the proper function of neuro-glial networks. Graded rises in [Ca\(^{2+}\)]\(_i\) result in the graded NO/cGMP production and, via cGMP-mediated Ca\(^{2+}\) influx and efflux from the cytosol, control the duration and the activation strength of downstream effector pathways. A disruption of this fine regulatory mechanism has a strong functional impact on endothelial and glial cells as well as neuronal signaling (Figure 2), making a further understanding of this interconnection highly relevant.

5. cGMP in Alzheimer’s Disease

Alzheimer’s disease is a neurodegenerative disorder characterized by a progressive loss of memory and a reduced capability for learning and memory formation. The main histopathological hallmarks of AD include the formation of amyloid plaques, accumulation of phosphorylated protein tau, formation of neurofibrillary tangles, neuroinflammation, and profound neuronal loss. Although AD pathology was first described in the early 20th century, the precise disease mechanism remains elusive. The amyloid hypothesis of AD posits that overproduction of amyloid-\(\beta\) (A\(\beta\)), produced by sequential cleavage of amyloid precursor protein (APP) by the \(\beta\)- and \(\gamma\)-secretases, leads to the formation of toxic A\(\beta\) species (oligomers and fibrils) precipitating in A\(\beta\)-plaques. According to this hypothesis, the increased production of self-aggregating forms of A\(\beta\) (e.g., A\(\beta\)42), due to missense mutations in the APP or other AD-related genes or failure in A\(\beta\) clearance, causes the gradual deposition of A\(\beta\) oligomers as diffuse plaques, microglial and astrocytic activation, oxidative injury, and formation of neurofibrillary tangles built of the hyperphosphorylated tau protein, together leading to widespread synaptic dysfunction and neuronal loss [152,153].

Having detrimental effects at high concentrations, at low concentrations, A\(\beta\) is important for memory formation (reviewed in [154]) and is known to be released in vivo in an activity-dependent manner [155]. It was shown that cGMP enhances the colocalization of APP with beta-site APP cleaving enzyme 1 (BASE-1) in endolysosomes, thus increasing the production of A\(\beta\) at synapses [156,157]. Furthermore, A\(\beta\) is needed for the cGMP-induced effects on LTP [157], known to be impaired in AD [158,159]. Next to synaptic dysfunction, A\(\beta\) can sustain low-grade neuroinflammation [160,161]. This inflammation can become neurotoxic, causing a disruption of neuronal signaling and even-
typically neuronal death [162,163]. Since cGMP signaling is essential for LTP and cGMP is a part of the inflammatory response (see above), deregulation of cGMP signaling likely contributes to the development of AD. Indeed, several studies succeeded in identifying AD-related changes in the NO/cGMP/cGK pathway (Figure 3). The first change regarding the cGMP signaling, identified in AD, was an increased expression of eNOS in neurons as well as nNOS in neurons and reactive astrocytes [164]. The upregulation of nNOS is associated with neuronal loss in the AD brain (Figure 3) [164,165]. It was also shown that the prolonged overactivation of nNOS induces synapse loss in motor neurons via the NO/cGMP/cGK pathway [93]. Differently from nNOS, eNOS in the AD brain seem to be downregulated in neurons (Figure 3) [166] but upregulated in astrocytes [18]. Interestingly, changed nNOS expression was shown to counteract dysregulated synaptic Ca\(^{2+}\) signaling at the early stages of amyloid deposition in animal models of AD [16]. In general, the vicinity of amyloid plaques is characterized by Ca\(^{2+}\) store-mediated neuronal hyperactivity [8,9,167]. By reducing presynaptic RyR-mediated Ca\(^{2+}\) release, NO signaling reduced synaptic transmission, thus counteracting neuronal hyperactivity [16].

![Figure 3](image-url)

**Figure 3.** Changes in cGMP-mediated signaling in Alzheimer’s disease. The levels of nNOS, iNOS, pGC-A, and NO are increased, and the activity of NO-GC is reduced. Furthermore, amyloid-β inhibits NO-GC activity. Whereas the cGMP concentration in the CSF is reduced, the mean effect on the intracellular cGMP level is unknown. Possible targets for AD treatment are the stimulation of NO-GC and the inhibition of PDE inhibitors (see text for further explanations). CD36: cluster of differentiation 36; ONOO\(^{-}\): peroxynitrate, all other abbreviations are explained in the figure legend for Figure 1.

As iNOS expression is associated with inflammation, and neuroinflammation is a major hallmark of AD, its expression is high in AD brains [168]. Contrary to the control aged brains, in AD brains, iNOS expression is induced not only in glial cells but also in neurons (Figure 3) [169,170]. Since iNOS is constitutively active, it produces large amounts of NO. A possibly toxic mechanism caused by NO overproduction is the accumulation of peroxynitrite (ONOO\(^{-}\)), through a reaction of NO with superoxide [171]. ONOO\(^{-}\) can cause nitrotyrosylation of proteins, leading to their dysfunction [25,172]. This effect takes place in animal models of AD as well as in AD brains [173,174]. Besides being a reactive nitrogen species itself, peroxynitrite can generate reactive oxygen species (ROS) [175], thus promoting mitochondrial dysfunction and cytotoxicity [25,172]. The reduction in ROS, for example, through synthetic or plant-based antioxidants, was shown to have anti-inflammatory and neuroprotective effects [176]. Therefore, future AD treatment might
benefit from a combination of antioxidant treatment with modifiers (see below) of the cGMP signaling pathway.

The activity of NO-GC decreases already in the aging brain [177] and is further downregulated in AD (Figure 3) [178]. Some inflammatory factors, such as IL-1β, LPS, and Aβ, can downregulate the expression, activity, and availability of NO-GC [179,180]. This effect was most prominent in human astrocytes located close to amyloid plaques [181]. Moreover, Aβ seems to inhibit NO-GC activity in microglia via binding to the cell surface receptor cluster of differentiation 36 (CD36) [115]. In neurons, so far, no AD-related downregulation of NO-GC was observed [181].

Little is known about the AD-related changes in NP-mediated signaling. However, in AD patients, the BNP levels were reported to decrease [38,182]. Additionally, Mahinrad et al. reported a significant increase in the NPR-A protein level in the brains of AD patients [38]. For ANP and CNP as well as NPR-C, there was a trend toward lower expression, which, however, did not reach the level of statistical significance [38]. PDEs are the third factor influencing the level of cGMP. No change in the expression levels of PDE2, 5, and 9 mRNA was found (Figure 3) [62], suggesting that the degradation of cGMP is not affected in AD. As for cGK, it was recently shown that it phosphorylates tau at Ser214 but not at Ser202, thereby likely reducing its pathological aggregation and shifting the protein from a pro-aggregant to a neuroprotective anti-aggregant conformation [183].

Although, as described above, many studies have been conducted on the proteins belonging to the NO/cGMP/cGK pathway, little is known about the overall AD-related changes in the cGMP concentration. In rat AD models, a reduction in the hippocampal cGMP concentration was identified [184]. Similarly, the severity of disease symptoms correlated with the severity of the cGMP reduction in the CSF, whereas the CSF cAMP levels did not change significantly [185,186]. In a mouse model of AD, the ability of the intrahippocampal NMDA infusion to stimulate cGMP production (measured by microdialysis) was significantly reduced already in young, amyloid-predepositing mice [187]. In contrast to WT animals, in AD mice, cGMP levels did not return to baseline but stayed elevated over a prolonged period of time. This suggests an impairment of the cGMP degradation by PDEs. So far, however, there are no data on AD-related changes in the intracellular cGMP concentration, but since the cumulative evidence points towards a decrease in the brain level of cGMP, PDE5 inhibitors have been tested as an AD treatment option. A potent PDE5 inhibitor, Sildenafil, able to cross the BBB, improved cognitive and memory functions in healthy rodents ([188–190] but see [191]). In Tg2576 mice, prolonged application of Sildenafil rescued cognitive impairment and lowered tau phosphorylation, with no change in Aβ load [192]. In APP/PS1 mice, the application of Sildenafil also resulted in improved cognitive performance. In contrast to Tg2576 animals, there was a reduction in soluble Aβ, which correlated with an increase in the phosphorylated CREB [191,193]. Furthermore, Sildenafil treatment reduced astrogliosis and microglia activation in several models of inflammation [194–196]. During inflammation, astrocytes increase the magnitude of ATP-induced Ca²⁺ signals, which was normalized by Sildenafil treatment [197].

In healthy young humans, no beneficial effect of Sildenafil on short-term memory was observed, besides a decrease in the reaction time [198]. Similarly, Sildenafil did not induce any significant improvement in auditory selective attention or verbal recognition memory [199]. However, in a recent drug repurposing study using an in silico approach based on insurance data from 7.23 million individuals, Sildenafil was identified as a target drug for AD treatment. In a 6-year-long follow-up, it was shown to reduce the risk of developing AD by 69% [200]. Moreover, recent pilot studies (10–20 patients) using a single dose (50 mg) of Sildenafil reported a Sildenafil-mediated decrease in the neural hyperactivity in the hippocampus and an increased cerebral metabolic rate of oxygen as well as cerebral blood flow [201,202]. Another PDE5 inhibitor, Tadalafil, has a longer half-life and better safety in chronic treatment [203], but lower capability to cross the BBB. However, during chronic administration of Tadalafil in a J20 AD model, sufficient PDE inhibition was found within the brain [204]. In this study, Tadalafil rescued cognitive deficits
and decreased tau hyperphosphorylation but did not affect Aβ load [204]. Furthermore, in acute slice experiments, Tadalafil was able to improve LTP in APP/PS1 mice [204].

Interestingly, PDE5 inhibitors can also induce autophagy [194,205]. Among others, autophagy is regulated via 8-nitro-cGMP (a product of the chemical reaction between NO and cGMP) and mTOR (mammalian target of rapamycin) and is essential for the clearance of aggregated Aβ and hyperphosphorylated tau [206,207]. PDE5 inhibitors induced autophagy by downregulating mTOR or by activating 5′ AMP-activated protein kinase [194,205]. Next to synthetic PDE inhibitors, there are also some natural compounds able to modulate cGMP signaling [208]. The flavonoid Icariside, obtained from epimedium brevicornum, and its derivate Icariin can inhibit PDE5 (Figure 3). Treatment of mouse (APP/PS1 animals) and rat (Aβ injection in the hippocampus) models of AD with these compounds decreased expression of APP, Aβ, and PDE5 and significantly attenuated AD-related cognitive deficits [209,210]. Further natural compounds, able to inhibit PDEs (for more details see [208]), were so far not tested in the preclinical AD models.

Recently, brain penetrant NO-GC stimulators have been developed as targets for AD treatment [103,211]. In vitro and in vivo studies with CYR119 revealed anti-inflammatory effects in murine microglia cell culture and the intact brain [103]. Furthermore, the BBB penetrant NO-GC stimulator CY6463 improved LTP in a Huntington’s disease mouse model and reduced loss of neuronal spines in a mouse model of AD (APP/PS1 mice). CY6463 was also able to improve cognitive function and reduce inflammatory markers in the brain [211]. So far, no results on clinical studies for the usage of these compounds in AD have been released (the first data of the phase 2 study on CY6463 are expected in July 2022; ClinicalTrials.gov Identifier: NCT04798989), but the preclinical studies show a great potential for sGC activators in AD treatment (Figure 3).

Taken together, the preclinical studies conducted so far point towards deregulation of the NO/cGMP/cGK signaling pathway in AD. However, as illustrated in Figure 3, this deregulation is complex and cell type-specific, and the extent as well as the direction of the change need further investigation.

6. Concluding Remarks and Future Directions

cGMP signaling controls the function of major cell types of the brain parenchyma and the vasculature both alone and in an interplay with intracellular Ca²⁺ signaling. Indeed, Ca²⁺ enhances NO production and increases the activity of the cGMP pathway. On the other hand, cGMP influences [Ca²⁺], by modulating the release of Ca²⁺ from the intracellular stores and the Ca²⁺ influx/efflux over the cell membrane. Although it is known that both signaling pathways are deregulated in AD, the interplay between the two has been largely neglected.

Given the complexity of the molecular mechanisms described above as well as the cellular players involved, this interplay must be studied in vivo. Current developments in the field of optical Ca²⁺ and cGMP Sensors [212–214] enable longitudinal in vivo imaging studies, allowing for intracellular data on [Ca²⁺] and cGMP at the subcellular resolution and over different stages of AD. This is extremely important because early neuronal hyperactivity [8,215] likely increases not only [Ca²⁺] but also NO and cGMP production, and decreased cGMP could enhance neuronal hypoactivity, found in late-stage AD [216,217].

Depending on the exact outcome of the longitudinal preclinical studies, individualized treatment options taking into account the sex (AD has a higher prevalence in women compared to men), disease stage, and the level of neuroinflammation can be developed. Fortunately, future therapies can choose from a rich cGMP-modulating toolkit containing BBB-permeant PDE inhibitors (e.g., Sildenafil, Tadalafil), NO-GC stimulators (e.g., CYR119, CY6463), etc. The hypothesis-driven development of such therapeutics is, however, impossible without a clear understanding of the direction and the extent of the modulation of NO/cGMP/cGK signaling pathway in aging and AD and its cell type-specific interplay with the intracellular Ca²⁺ signaling.
Author Contributions: Conceptualization, O.G. and A.J.; writing—original draft preparation, A.J.; writing—review and editing, O.G.; visualization, A.J. and O.G.; supervision, O.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially funded by Alexander von Humboldt-Stiftung, grant number 1026649 to O.G.

Acknowledgments: The authors thank A. Kaupp for help with the preparation of the figures.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Hofmann, F. The CGMP System: Components and Function. Biol. Chem. 2020, 401, 447–469. [CrossRef] [PubMed]
2. Goldstein, I.; Burnett, A.L.; Rosen, R.C.; Park, P.W.; Stecher, V.J. The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. Sex. Med. Rev. 2019, 7, 115–128. [CrossRef] [PubMed]
3. Rutten, K.; Van Donkelaar, E.L.; Ferrington, L.; Blokland, A.; Bollen, E.; Steinbusch, H.W.M.; Kelly, P.A.T.; Prickaerts, J.H. Phosphodiesterase Inhibitors Enhance Object Memory Independent of Cerebral Blood Flow and Glucose Utilization in Rats. Neuropsychopharmacology 2009, 34, 1914–1925. [CrossRef] [PubMed]
4. Yang, G.; Iadecola, C. Activation of Cerebellar Climbing Fibers Increases Cerebellar Blood Flow: Role of Glutamate Receptors, Nitric Oxide, and CGMP. Stroke 1998, 29, 499–508. [CrossRef] [PubMed]
5. Garthwaite, J.; Charles, S.L.; Chess-Williams, R. Endothelium-Derived Relaxing Factor Release on Activation of NMDA Receptors Suggests Role as Intercellular Messenger in the Brain. Nature 1988, 336, 385–388. [CrossRef]
6. Weissman, B.A.; Jones, C.L.; Liu, Q.; Gross, S.S. Activation and Inactivation of Neuronal Nitric Oxide Synthase: Characterization of Ca2+-Dependent [125I]Calmodulin Binding. Eur. J. Pharmacol. 2002, 435, 9–18. [CrossRef]
7. Palop, J.J.; Mucke, L. Network Abnormalities and Intervertebrum Dysfunction in Alzheimer Disease. Nat. Rev. Neurosci. 2016, 17, 777–792. [CrossRef]
8. Busche, M.A.; Eichhoff, G.; Adelsberger, H.; Abramowski, D.; Wiederhold, K.-H.; Haass, C.; Steffen, M.; Konnerth, A.; Garaschuk, O. Clusters of Hyperactive Neurons near Amyloid Plaques in a Mouse Model of Alzheimer’s Disease. Science 2008, 321, 1686–1689. [CrossRef]
9. Lerdkrai, C.; Asavapanumas, N.; Brawek, B.; Kovalchuk, Y.; Motahedi, N.; Del Moral, M.O.; Garaschuk, O. Intracellular Ca2+ Stores Control in Vivo Neuronal Hyperactivity in a Mouse Model of Alzheimer’s Disease. Proc. Natl. Acad. Sci. USA 2018, 115, E1279–E1288. [CrossRef]
10. Brawek, B.; Garaschuk, O. Network-Wide Dysregulation of Calcium Homeostasis in Alzheimer’s Disease. Cell Tissue Res. 2014, 357, 427–438. [CrossRef]
11. Brawek, B.; Schwendele, B.; Riester, K.; Kohsaka, S.; Lerdkrai, C.; Liang, Y.; Garaschuk, O. Impairment of in Vivo Calcium Signaling in Amyloid Plaque-Associated Microglia. Acta Neuropathol. 2014, 127, 495–505. [CrossRef]
12. Kuchibhotla, K.V.; Lattarulo, C.R.; Hyman, B.T.; Bacskai, B.J. Synchronous Hyperactivity and Intercellular Calcium Waves in Alzheimer’s Disease. Cell Tissue Res. 2012, 349, 213–222. [CrossRef] [PubMed]
13. Wiessman, B.A.; Jones, C.L.; Liu, Q.; Gross, S.S. Activation and Inactivation of Neuronal Nitric Oxide Synthase: Characterization of Ca2+-Dependent [125I] Calmodulin Binding. Eur. J. Pharmacol. 2002, 435, 9–18. [CrossRef]
14. Verkhratsky, A.; Li, Q.; Melino, S.; Melino, G.; Shi, Y. Can COVID-19 Pandemic Boost the Epidemic of Neurodegenerative Diseases? Brain Res. 2019, 17, 135–144. [CrossRef] [PubMed]
15. Lüth, H.J.; Holzer, M.; Gärtner, U.; Staufenbiel, M.; Arendt, T. Expression of Endothelial and Inducible NOS-Isoforms Is Increased in Alzheimer’s Disease, in APP23 Transgenic Mice and after Experimental Brain Lesion in Rat: Evidence for an Induction by Amyloid Pathology. Brain Res. 2001, 913, 57–67. [CrossRef]
16. Brawek, B.; Schwendele, B.; Riester, K.; Kohsaka, S.; Lerdkrai, C.; Liang, Y.; Garaschuk, O. Impairment of in Vivo Calcium Signaling in Amyloid Plaque-Associated Microglia. Acta Neuropathol. 2014, 127, 495–505. [CrossRef]
17. Chakroborty, S.; Kim, J.; Schneider, C.; West, A.R.; Stutzmann, G.E. Nitric Oxide Signaling Is Recruited As a Compensatory Mechanism for Sustaining Synaptic Plasticity in Alzheimer’s Disease Mice. J. Neurosci. 2015, 35, 6893–6902. [CrossRef] [PubMed]
18. Lüth, H.J.; Holzer, M.; Gärtner, U.; Staufenbiel, M.; Arendt, T. Expression of Endothelial and Inducible NOS-Isoforms Is Increased in Alzheimer’s Disease, in APP23 Transgenic Mice and after Experimental Brain Lesion in Rat: Evidence for an Induction by Amyloid Pathology. Brain Res. 2001, 913, 57–67. [CrossRef]
19. Wiencken, A.E.; Casagrande, V.A. Endothelial Nitric Oxide Synthetase (ENOS) in Astrocytes: Another Source of Nitric Oxide in Normal Adult Rat Brain. Brain Res. 1996, 714, 135–144. [CrossRef] [PubMed]
20. Abu-Soud, H.M.; Stuehr, D.J. Nitric Oxide Synthases Reveal a Role for Calmodulin in Controlling Electron Transfer. Proc. Natl. Acad. Sci. USA 1993, 90, 10769. [CrossRef]
21. Busse, R.; Mülisch, A. Calcium-Dependent Nitric Oxide Synthesis in Endothelial Cytosol Is Mediated by Calmodulin. FEBS Lett. 1990, 265, 133–136. [CrossRef]
22. Sheng, W.; Zong, Y.; Mohammad, A.; Ajit, D.; Cui, J.; Han, D.; Hamilton, J.L.; Simonyi, A.; Sun, A.Y.; Gu, Z.; et al. Pro-Inflammatory Cytokines and Lipopolysaccharide Induce Changes in Cell Morphology, and Upregulation of ERK1/2, iNOS and SLP-A2-IA in Astrocytes and Microglia. *J. Neuroinflamm.* 2011, 8, 121. [CrossRef]

23. Heneka, M.T.; Feinstein, D.L. Expression and Function of Inducible Nitric Oxide Synthase in Neurons. *J. Neuroimmunol.* 2001, 114, 8–18. [CrossRef]

24. Colasanti, M.; Persichini, T.; Di Puccio, T.; Gremo, F.; Lauro, G.M. Human Ramified Microglial Cells Produce Nitric Oxide upon Escherichia Coli Lipopolysaccharide and Tumor Necrosis Factor α Stimulation. *Neurosci. Lett.* 1995, 200, 144–146. [CrossRef]

25. Lushchak, V.I.; Duszenko, M.; Gospodaryov, D.V.; Garaschuk, O. Oxidative Stress and Energy Metabolism in the Brain: Midlife as a Turning Point. *Antioxidants* 2021, 10, 1715. [CrossRef]

26. Kleinert, H.; Euchenehofer, C.; Illrig-Biedert, I.; Förstermann, U. In Murine 3T3 Fibroblasts, Different Second Messenger Pathways Resulting in the Induction of NO Synthase II (iNOS) Converge in the Activation of Transcription Factor NF-KB. *J. Biol. Chem.* 1996, 271, 6039–6044. [CrossRef]

27. Jia, J.; Liu, Y.; Zhang, X.; Liu, X.; Qi, J. Regulation of iNOS Expression by NF-KB in Human Lens Epithelial Cells Treated with High Levels of Glucose. *Investig. Ophthalmal. Vis. Sci.* 2013, 54, 5070–5077. [CrossRef]

28. Um, H.C.; Jang, J.H.; Kim, D.H.; Lee, C.; Surh, Y.J. Nitric Oxide Activates Nrf2 through S-Nitrosoylation of Keap1 in PC12 Cells. *Nitric Oxide* 2011, 25, 161–168. [CrossRef]

29. Iizumi, T.; Takahashi, S.; Mashima, K.; Minami, K.; Izawa, Y.; Abe, T.; Hishiki, T.; Suematsu, M.; Kajimura, M.; Suzuki, N. A Possible Role of Microglia-Derived Nitric Oxide by Lipopolysaccharide in Activation of Astroglial Pentose-Phosphate Pathway via the Keap1/Nrf2 System. *J. Neuroinflamm.* 2016, 13, 99. [CrossRef]

30. Russwurm, M.; Wittau, N.; Koelsing, D. Guanylyl Cyclase/PSD-95 Interaction: Targeting of the Nitric Oxide-Sensitive A2B1 Guanylyl Cyclase to Synaptic Membranes. *J. Biol. Chem.* 2001, 276, 44647–44652. [CrossRef]

31. Zabel, U.; Häusler, C.; Weeger, M.; Schmidt, H.H.H.W. Homodimerization of Soluble Guanylyl Cyclase Subunits: Dimerization analysis using a glutathione-transferase affinity tag. *J. Biol. Chem.* 1999, 274, 18149–18152. [CrossRef][PubMed]

32. Derbyshire, E.R.; Marletta, M.A. Structure and Regulation of Soluble Guanylate Cyclase. *Annu. Rev. Biochem.* 2012, 81, 533–559. [CrossRef][PubMed]

33. Purohit, R.; Weichsel, A.; Montfort, W.R. Crystal Structure of the Alpha Subunit PAS Domain from Soluble Guanylyl Cyclase. *Science* 2013, 343, 1439. [CrossRef]

34. Allerston, C.K.; von Delft, F.; Gileadi, O. Crystal Structures of the Catalytic Domain of Human Soluble Guanylyl Cyclase. *PLoS ONE* 2013, 8, e57644. [CrossRef]

35. Ma, X.; Beuve, A.; Van Den Akker, F. Crystal Structure of the Signaling Helix Coiled-Coil Domain of the Beta1 Subunit of the Soluble Guanylyl Cyclase. *BMC Struct. Biol.* 2010, 10, 2. [CrossRef]

36. Pan, J.; Yuan, H.; Zhang, X.; Zhang, H.; Xu, Q.; Zhou, Y.; Tan, L.; Nagawa, S.; Huang, Z.X.; Tan, X. Probing the Molecular Mechanism of Human Soluble Guanylyl Cyclase Activation by NO In Vitro and In Vivo. *Sci. Rep.* 2017, 7, 43112. [CrossRef][PubMed]

37. Mergia, E.; Russwurm, M.; Zoidl, G.; Koelsing, D. Major Occurrence of the New A2B1 Isoform of NO-Sensitive Guanylyl Cyclase in Brain. *Cell. Signal.* 2003, 15, 189–195. [CrossRef]

38. Mahinrad, S.; Bulk, M.; Van Der Velpen, I.; Mahfouz, A.; Van Roorn-Mom, W.; Fedarko, N.; Yasar, S.; Sabayan, B.; Van Heemst, D.; Van Der Weerd, L. Natriuretic Peptides in Post-Mortem Brain Tissue and Cerebrospinal Fluid of Non-Demented Humans and Alzheimer’s Disease Patients. *Front. Neurosci.* 2018, 12, 864. [CrossRef]

39. Maack, T.; Suzuki, M.; Almeida, F.A.; Nussenzveig, D.; Scarborough, R.M.; Mcnroe, G.A.; Lewicki, J.A. Physiological Role of Silent Receptors of Atrial Natriuretic Factor. *Science* 1987, 238, 675–678. [CrossRef]

40. Sjöstedt, E.; Zhong, W.; Fagerberg, L.; Karlsson, M.; Mitsios, N.; Adori, C.; Oksvold, P.; Edfors, F.; Limiszewska, A.; Hickmet, F.; et al. An Atlas of the Protein-Coding Genes in the Human, Pig, and Mouse Brain. *Biochem. Biophys. Res. Commun.* 1988, 155, 733–739. [CrossRef]

41. Takahashi, K.; Totsume, K.; Sone, M.; Ohneda, M.; Murakami, O.; Itoi, K.; Mouri, T. Human Brain Natriuretic Peptide-like Immunoreactivity in Human Brain. *Peptides* 1992, 13, 121–123. [CrossRef]

42. Zamir, N.; Skoﬁtisch, G.; Eskay, R.L.; Jacobowitz, D.M. Distribution of Immunoreactive Atrial Natriuretic Peptide in the Central Nervous System of the Rat. *Brain Res.* 1986, 365, 105–111. [CrossRef]

43. Hölsli, E.; Hölsli, L. Autoradiographic Localization of Binding Sites for Arginine Vasopressin and Atrial Natriuretic Peptide on Astrocytes and Neurons of Cultured Rat Central Nervous System. *Neuroscience* 1992, 51, 159–166. [CrossRef]

44. Teunissen, C.; Steinbusch, H.; Markerink-van Ittersum, M.; Koelsing, D.; De Vente, J. Presence of Soluble and Particulate Guanylyl Cyclase in the Same Hippocampal Astrocytes. *Brain Res.* 2001, 891, 206–212. [CrossRef]

45. Ogawa, Y.; Nakao, K.; Nakagawa, O.; Komatsu, Y.; Hosoda, K.; Suga, S.I.; Arai, H.; Nagata, K.; Yoshida, N.; Imura, H. Human C-Type Natriuretic Peptide. Characterization of the Gene and Peptide. *Hypertension* 1992, 19, 809–813. [CrossRef]

46. De Vente, J.; Anan, E.; Gambaryan, S.; Markerink-van Ittersum, M.; Axer, H.; Gallatz, K.; Lohmann, S.M.; Palkovits, M. Localization of CGMP-Dependent Protein Kinase Type II in Rat Brain. *Neuroscience* 2001, 108, 27–49. [CrossRef]

47. Hofmann, F. The Biology of Cyclic GMP-Dependent Protein Kinases. *J. Biol. Chem.* 2005, 280, 1–4. [CrossRef]

48. El-Husseini, A.E.; Bladen, C.; Vincent, S.R. Molecular Characterization of a Type II Cyclic GMP-Dependent Protein Kinase Expressed in the Rat Brain. *J. Neurochem.* 1995, 64, 2814–2817. [CrossRef]
50. Lincoln, T.M.; Dills, W.L.; Corbin, J.D. Purification and Subunit Composition of Guanosine 3′:5′-Monophosphate-Dependent Protein Kinase from Bovine Lung. J. Biol. Chem. 1977, 252, 4269–4275. [CrossRef]
51. Wolfe, L.; Corbin, J.D.; Francis, S.H. Characterization of a Novel Isozyme of CGMP-Dependent Protein Kinase from Bovine Aorta. J. Biol. Chem. 1989, 264, 7734–7741. [CrossRef]
52. Glass, D.B.; Smith, S.B. Phosphorylation by Cyclic GMP-Dependent Protein Kinase of a Synthetic Peptide Corresponding to the Autophosphorylation Site in the Enzyme. J. Biol. Chem. 1983, 258, 14797–14803. [CrossRef]
53. Chu, D.-M.; Francis, S.H.; Thomas, J.W.; Maksymovitch, E.A.; Fosler, M.; Corbin, J.D. Activation by Autophosphorylation or CGMP Binding Produces a Similar Apparent Conformational Change in CGMP-Dependent Protein Kinase. J. Biol. Chem. 1998, 273, 14649–14656. [CrossRef]
54. Werner, C.; Raivich, G.; Cowen, M.; Strekalova, T.; Sillaber, I.; Buters, J.T.; Spanagel, R.; Hofmann, F. Importance of NOcGMP Signalling via CGMP-Dependent Protein Kinase II for Controlling Emotionality and Neurobehavioural Effects of Alcohol. Eur. J. Neurosci. 2004, 20, 3498–3506. [CrossRef]
55. Paul, C.; Schöberl, F.; Weinmeister, P.; Micale, V.; Wotjak, C.T.; Hofmann, F.; Kleppisch, T. Signaling through CGMP-Dependent Protein Kinase I in the Amygdala Is Critical for Auditory-Cued Fear Memory and Long-Term Potentiation. J. Neurosci. 2008, 28, 14202–14212. [CrossRef]
56. Reyes-Irisarri, E.; Markerink-Van Ittersum, M.; Mengod, G.; De Vente, J. Expression of the CGMP-Specific Phosphodiesterases 2 and 3 in Normal and Alzheimer’s Disease Human Brains. Eur. J. Neurosci. 2007, 25, 3332–3338. [CrossRef]
57. Andreeva, S.G.; Dikkes, P.; Epstein, P.M.; Rosenberg, P.A. Expression of CGMP-Specific Phosphodiesterase 9A MRNA in the Rat Brain. J. Neurosci. 2001, 21, 9068–9076. [CrossRef] [PubMed]
58. Biel, M.; Zong, X.; Hofmann, F. Molecular Diversity of Cyclic Nucleotide-Gated Cation Channels. Natuyn. Schmiedebergs Arch. Pharmacol. 1995, 353, 1–10. [CrossRef]
59. Paul, C.; Schöberl, F.; Weinmeister, P.; Micale, V.; Wotjak, C.T.; Hofmann, F.; Kleppisch, T. Signaling through CGMP-Dependent Protein Kinase I in the Amygdala Is Critical for Auditory-Cued Fear Memory and Long-Term Potentiation. J. Neurosci. 2008, 28, 14202–14212. [CrossRef]
60. Barnstable, C.J.; Wei, J.Y.; Han, M.H. Modulation of Synaptic Function by CGMP and CGMP-Gated Cation Channels. Nature 1985, 313, 310–313. [CrossRef]
61. Reyes-Irisarri, E.; Markerink-Van Ittersum, M.; Mengod, G.; De Vente, J. Expression of the CGMP-Specific Phosphodiesterases 2 and 3 in Normal and Alzheimer’s Disease Human Brains. Eur. J. Neurosci. 2007, 25, 3332–3338. [CrossRef] [PubMed]
62. Son, H.; Lu, Y.F.; Zhuo, M.; Arancio, O.; Kandel, E.R.; Hawkins, R.D. The Specific Role of CGMP in Hippocampal LTP. Learn. Mem. 1998, 5, 231–245. [CrossRef]
63. Andaivea, S.G.; Dikkes, P.; Epstein, P.M.; Rosenberg, P.A. Expression of CGMP-Specific Phosphodiesterase 9A MRNA in the Rat Brain. J. Neurosci. 2001, 21, 9068–9076. [CrossRef] [PubMed]
64. Surapisitchat, J.; Jeon, K.I.; Yan, C.; Beavo, J.A. Differential Regulation of Endothelial Cell Permeability by CGMP via Phosphodiesterases 2 and 3. Circ. Res. 2007, 101, 811–818. [CrossRef]
65. Rybalkin, S.D.; Rybalkina, I.G.; Fei, R.; Hofmann, F.; Beavo, J.A. Regulation of CGMP-Specific Phosphodiesterase (PDE5) Phosphorylation in Smooth Muscle Cells. J. Biol. Chem. 2002, 277, 3310–3317. [CrossRef]
66. Lee, D.I.; Zhu, G.; Sasaki, T.; Cho, G.S.; Hamdani, N.; Holewinski, R.; Jo, S.H.; Danner, T.; Zhang, M.; Rainer, P.P.; et al. Phosphodiesterase 9A Controls Nitric-Oxide Independent CGMP and Hypertrophic Heart Disease. Nature 2015, 519, 472. [CrossRef]
67. Murthy, K.S. Activation of Phosphodiesterase 5 and Inhibition of Guanylate Cyclase by CGMP-Dependent Protein Kinase in Smooth Muscle. Biochem. Int. 2001, 50, 360, 199. [CrossRef]
68. Zhou, Z.; Seyed, N.; Pyriochou, A.; Roussos, C.; Fulton, D.; Beuve, A.; Papapetropoulos, A. Protein Kinase G Phosphorylates Soluble Guanylyl Cyclase on Serine 64 and Inhibits Its Activity. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1803. [CrossRef]
69. Anthony Altar, C.; Boyar, W.C.; Kim, H.S. Discriminatory Roles for D1 and D2 Dopamine Receptor Subtypes in the in Vivo Control of Neostriatal Cyclic GMP. Eur. J. Pharmacol. 1990, 181, 17–21. [CrossRef]
70. Mathes, C.; Thompson, S.H. The Nitric Oxide/CGMP Pathway Couples Muscarinic Receptors to the Activation of Ca2+ Influx. J. Neurosci. 1996, 16, 1702–1709. [CrossRef]
71. De Vente, J.; Markerink-Van Ittersum, M.; Axer, H.; Steinbusch, H.W.M. Nitric-Oxide-Induced CGMP Synthesis in Cholinergic Neurons in the Rat Brain. Exp. Brain Res. 2001, 136, 480–491. [CrossRef]
72. Piedrafita, B.; Cauil, O.; Montolou, C.; Felipe, V. The Function of the Guanulate-Nitric Oxide-CGMP Pathway in Brain in Vivo and Learning Ability Decrease in Parallel in Mature Compared with Young Rats. Learn. Mem. 2007, 14, 254–258. [CrossRef]
73. Christopherson, K.S.; Hiltier, B.J.; Lim, W.A.; Bredt, D.S. PSD-95 Assembles a Ternary Complex with the N-Methyl-D-Aspartic Acid Receptor and a Bivalent Neuronal NO Synthase PDZ Domain. J. Biol. Chem. 1999, 274, 27467–27473. [CrossRef]
74. Gudi, T.; Lohmann, S.M.; Pilz, R.B. Regulation of Gene Expression by Cyclic GMP-Dependent Protein Kinase Requires Nuclear Translocation of the Kinase: Identification of a Nuclear Localization Signal. Mol. Cell. Biol. 1997, 17, 5244–5254. [CrossRef]
75. Gudi, T.; Casteel, D.E.; Vinson, C.; Boss, G.R.; Pilz, R.B. NO Activation of Fos Promoter Elements Requires Nuclear Translocation of G-Kinase I and CREB Phosphorylation but Is Independent of MAP Kinase Activation. Oncogene 2000, 19, 6324–6333. [CrossRef]
76. Casteel, D.E.; Zhang, T.; Zhuang, S.; Pilz, R.B. CGMP-Dependent Protein Kinase Anchoring by IRAG Regulates Its Nuclear Translocation and Transcriptional Activity. Cell. Signal. 2008, 20, 1392–1399. [CrossRef]
77. Seo, S.Y.; Oh, J.H.; Choe, E.S. Protein Kinase G Increases AMPA Receptor GluR1 Phosphorylation at Serine 845 after Repeated Cocaine Administration in the Rat Nucleus Accumbens. *Neurosci. Lett.* 2013, 544, 147–151. [CrossRef]

78. Serulle, Y.; Zhang, S.; Ninan, I.; Puzzo, D.; McCarthey, M.; Khatri, L.; Arancio, O.; Ziff, E.B. A GluR1-CGKII Interaction Regulates AMPA Receptor Trafficking. *Neuron* 2007, 56, 670–688. [CrossRef]

79. Burette, A.; Zabel, U.; Weinberg, R.J.; Schmidt, H.H.H.W.; Valtschanoff, J.G. Synaptic Localization of Nitric Oxide Synthase and Soluble Guanylyl Cyclase in the Hippocampus. *J. Neurosci.* 2002, 22, 8961–8970. [CrossRef]

80. Ogawa, H.; Mizusawa, A.; Kikuchi, Y.; Hida, W.; Miki, H.; Shirato, K. Nitric Oxide as a Retrograde Messenger in the Nucleus Tractus Solitarii of Rats during Hypoxia. *J. Physiol.* 1995, 486, 495–504. [CrossRef]

81. O’Dell, T.J.; Hawkins, R.D.; Kandel, E.R.; Arancio, O. Tests of the Roles of Two Diffusible Substances in Long-Term Potentiation: Evidence for Nitric Oxide as a Possible Early Retrograde Messenger. *Proc. Natl. Acad. Sci. USA* 1991, 88, 11285. [CrossRef] [PubMed]

82. Arancio, O.; Lev-Ram, V.; Tsien, R.Y.; Kandel, E.R.; Hawkins, R.D. Nitric Oxide Acts as a Retrograde Messenger during Long-Term Potentiation in Cultured Hippocampal Neurons. *J. Physiol.* 1996, 90, 321–322. [CrossRef]

83. Neitz, A.; Mergia, E.; Eysel, U.T.; Koesling, D.; Mittmann, T. Presynaptic Nitric Oxide/CGMP Facilitates Glutamate Release via Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels in the Hippocampus. *Eur. J. Neurosci.* 2011, 33, 1611–1621. [CrossRef] [PubMed]

84. Speigel, I.; Osman, V.; Hemmings, H.C. Volatile Anesthetics Inhibit Presynaptic CGMP Signaling to Depress Presynaptic Excitability in Rat Hippocampal Neurons. *Biochim. Biophys. Acta* 2022. [CrossRef]

85. Caviedes, A.; Varas-Godoy, M.; Lafourcade, C.; Sandoval, S.; Bravo-Alegria, J.; Kaehe, T.; Massmann, A.; Figueroa, J.P.; Nualart, E. The Role of CGMP-Dependent Signaling Pathway in Synaptic Vesicle Exoendocytic Coupling of Synaptic Vesicles. *Biochim. Biophys. Acta* 2022. [CrossRef]

86. Petrov, A.M.; Giniatullin, A.R.; Sitdikova, G.F.; Zefirov, A.L. The Role of CGMP-Dependent Signaling Pathway in Synaptic Vesicle Exoendocytic Coupling of Synaptic Vesicles. *Biochim. Biophys. Acta* 2022. [CrossRef]

87. Arancio, O.; Lev-Ram, V.; Tsien, R.Y.; Kandel, E.R.; Hawkins, R.D. Nitric Oxide Acts as a Retrograde Messenger during Long-Term Potentiation in Cultured Hippocampal Neurons. *J. Physiol.* 1996, 90, 321–322. [CrossRef]

88. Lin, W.H.; Nebhan, C.A.; Anderson, B.R.; Webb, D.J. Vasodilator-Stimulated Phosphoprotein (VASP) Induces Actin Assembly Chain Phosphorylation. *J. Biol. Chem.* 2008, 283, 36010–36020. [CrossRef]

89. Wang, H.G.; Lu, F.M.; Jin, I.; Udo, H.; Kandel, E.R.; De Vente, J.; Walter, U.; Lohmann, S.M.; Hawkins, R.D.; Antonova, I. Presynaptic and Postsynaptic Roles of NO, CGK, and RhoA in Long-Lasting Potentiation and Aggregation of Synaptic Proteins. *Neuron* 2005, 45, 389–403. [CrossRef]

90. Achar, S.; Saha, R.N.; Giri, S.; Stenzel-Poore, M.; Pahan, K. Regulation of Inducible Nitric Oxide Synthase in Proinflammatory and Myelination Processes. *Free Radic. Biol. Med.* 2014, 60, 147–151. [CrossRef]

91. Arbona, A.; Hidalgo, A.; Schonrock, C.; Torres, M. The Regulation of Synaptic Vesicle Recycling by CGMP-Dependent Protein Kinase Type II in Cerebellar Granule Cells under Strong and Sustained Stimulation. *J. Neurosci.* 2014, 34, 8788. [CrossRef]

92. Wang, H.G.; Lu, F.M.; Jin, I.; Udo, H.; Kandel, E.R.; De Vente, J.; Walter, U.; Lohmann, S.M.; Hawkins, R.D.; Antonova, I. Presynaptic and Postsynaptic Roles of NO, CGK, and RhoA in Long-Lasting Potentiation and Aggregation of Synaptic Proteins. *Neuron* 2005, 45, 389–403. [CrossRef]

93. Aragona, A.; Hidalgo, A.; Schonrock, C.; Torres, M. The Regulation of Synaptic Vesicle Recycling by CGMP-Dependent Protein Kinase Type II in Cerebellar Granule Cells under Strong and Sustained Stimulation. *J. Neurosci.* 2014, 34, 8788. [CrossRef]

94. Achar, S.; Saha, R.N.; Giri, S.; Stenzel-Poore, M.; Pahan, K. Regulation of Inducible Nitric Oxide Synthase in Proinflammatory and Myelination Processes. *Free Radic. Biol. Med.* 2014, 60, 147–151. [CrossRef]

95. Achar, S.; Saha, R.N.; Giri, S.; Stenzel-Poore, M.; Pahan, K. Regulation of Inducible Nitric Oxide Synthase in Proinflammatory and Myelination Processes. *Free Radic. Biol. Med.* 2014, 60, 147–151. [CrossRef]

96. Achar, S.; Saha, R.N.; Giri, S.; Stenzel-Poore, M.; Pahan, K. Regulation of Inducible Nitric Oxide Synthase in Proinflammatory and Myelination Processes. *Free Radic. Biol. Med.* 2014, 60, 147–151. [CrossRef]

97. Achar, S.; Saha, R.N.; Giri, S.; Stenzel-Poore, M.; Pahan, K. Regulation of Inducible Nitric Oxide Synthase in Proinflammatory and Myelination Processes. *Free Radic. Biol. Med.* 2014, 60, 147–151. [CrossRef]

98. Achar, S.; Saha, R.N.; Giri, S.; Stenzel-Poore, M.; Pahan, K. Regulation of Inducible Nitric Oxide Synthase in Proinflammatory and Myelination Processes. *Free Radic. Biol. Med.* 2014, 60, 147–151. [CrossRef]

99. Achar, S.; Saha, R.N.; Giri, S.; Stenzel-Poore, M.; Pahan, K. Regulation of Inducible Nitric Oxide Synthase in Proinflammatory and Myelination Processes. *Free Radic. Biol. Med.* 2014, 60, 147–151. [CrossRef]
127. Steiner, O.; Coisne, C.; Cecchelli, R.; Boscai, R.; Deutsch, U.; Engelhardt, B.; Lyck, R. Differential Roles for Endothelial ICAM-1, ICAM-2, and VCAM-1 in Shear-Resistant T Cell Arrest, Polarization, and Directed Crawling on Blood-Brain Barrier Endothelium. J. Immunol. 2010, 185, 4846–4855. [CrossRef]

128. Wong, D.; Dorovini-Zis, K.; Vincent, S.R. Cytokines, Nitric Oxide, and CGMP Modulate the Permeability of an in Vitro Model of the Human Blood–Brain Barrier. Exp. Neurol. 2004, 190, 446–455. [CrossRef]

129. Liu, S.M.; Sundqvist, T. Nitric Oxide and CGMP Regulate Endothelial Permeability and F-Actin Distribution in Hydrogen Peroxide-Treated Endothelial Cells. Exp. Cell Res. 1997, 235, 238–244. [CrossRef]

130. Attwell, D.; Mishra, A.; Hall, C.N.; O’Farrell, F.M.; Dalkara, T. What Is a Pericyte? J. Cereb. Blood Flow Metab. 2016, 36, 451. [CrossRef]

131. Sakagami, K.; Kawamura, H.; Wu, D.M.; Puro, D.G. Nitric Oxide/CGMP-Induced Inhibition of Calcium and Chloride Currents in Retinal Pericytes. Microvasc. Res. 2001, 62, 196–203. [CrossRef]

132. Fessenden, J.D.; Schacht, J. Localization of Soluble Guanylate Cyclase Activity in the Guinea Pig Cochlea Suggests Involvement in Regulation of Blood Flow and Supporting Cell Physiology. J. Histochem. Cytochem. 1997, 45, 1401–1408. [CrossRef]

133. Tian, F.; Fessenden, J.D.; Schacht, J. Cyclic GMP-Dependent Protein Kinase-I in the Guinea Pig Cochlea. Hear. Res. 1999, 131, 63–70. [CrossRef]

134. Bourque, S.L.; Davidge, S.T.; Adams, M.A. The Interaction between Endothelin-1 and Nitric Oxide in the Vasculature: New Perspectives. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300, 1288–1295. [CrossRef]

135. Komeima, K.; Hayashi, Y.; Naito, Y.; Watanabe, Y. Inhibition of Neuronal Nitric-Oxide Synthase by Calcium/Calmodulin-Dependent Protein Kinase Ila through Ser847 Phosphorylation in NG108-15 Neuronal Cells. J. Biol. Chem. 2000, 275, 28139–28143. [CrossRef]

136. Hayashi, Y.; Nishio, M.; Naito, Y.; Yokokura, H.; Nimura, Y.; Hidaka, H.; Watanabe, Y. Regulation of Neuronal Nitric-Oxide Synthase by Calmodulin Kinases. J. Biol. Chem. 1999, 274, 20597–20602. [CrossRef]

137. Peunova, N.; Enikolopov, G. Amplification of Calcium-Induced Gene Transcription by Nitric Oxide in Neuronal Cells. Nature 1993, 364, 450–453. [CrossRef] [PubMed]

138. Lee, S.A.; Bae, H.R.; Park, J.K.; Kang, E.K.; Bae, K.W.; Park, H.T. Calmodulin-Dependent Activation of P38 and P42/44 Mitogen-Activated Protein Kinases Contributes to c-Fos Expression by Calcium in PC12 Cells: Modulation by Nitric Oxide. Brain Res. Mol. Brain Res. 2000, 75, 16–24. [CrossRef]

139. Omori, K.; Kotera, J. Overview of PDEs and Their Regulation. Circ. Res. 2007, 100, 309–327. [CrossRef] [PubMed]

140. Zolle, O.; Lawrie, A.M.; Simpson, A.W.M. Activation of the Particulate and Not the Soluble Guanylate Cyclase Leads to the Inhibition of Ca²⁺ Extrusion through Localized Elevation of CGMP*. J. Biol. Chem. 2000, 275, 25892–25899. [CrossRef] [PubMed]

141. Konopacka, A.; Zielinska, M.; Albrecht, J. Ammonia Inhibits the C-Type Natriuretic Peptide-Dependent Cyclic GMP Synthesis and Calcium Accumulation in a Rat Brain Endothelial Cell Line. Neurochem. Int. 2008, 52, 1160–1166. [CrossRef]

142. Kubo, S.H.; Atlas, S.A.; Laragh, J.H.; Cody, R.J. Maintenance of Forearm Vasodilator Action of Atrial Natriuretic Factor in Normotensive Subjects. J. Hypertens. 1986, 4, 704–711. [CrossRef] [PubMed] [PubMed Central]

143. Verkhratsky, A. Glial Calcium Signaling in Physiology and Pathophysiology 1. J. Neurophysiol. 2002, 88, 1270–1278. [CrossRef]

144. Verkhratsky, A. Glial Calcium Signaling in Physiology and Pathophysiology 2. J. Neurophysiol. 2002, 88, 1279–1288. [CrossRef]

145. Willmott, N.J.; Wong, D.; Strong, A.J. A Fundamental Role for the Nitric Oxide-G-Kinase Signaling Pathway in Mediating Intercellular Ca²⁺ Waves in Glia. J. Neurosci. 2000, 20, 1767–1777. [CrossRef]

146. Krzan, M.; Stenovec, M.; Kretf, M.; Pangršić, T.; Grilc, S.; Haydon, P.G.; Zorec, R. Calcium-Dependent Exocytosis of Atrial Natriuretic Peptide from Astrocytes. J. Astrocytes. 2003, 23, 1580–1583. [CrossRef]

147. Kubo, S.H.; Atlas, S.A.; Laragh, J.H.; Cody, R.J. Maintenance of Forearm Vasodilator Action of Atrial Natriuretic Factor in Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. Am. J. Cardiol. 1992, 69, 1306–1309. [CrossRef]

148. Steiner, O.; Coisne, C.; Cecchelli, R.; Boscai, R.; Deutsch, U.; Engelhardt, B.; Lyck, R. Differential Roles for Endothelial ICAM-1, ICAM-2, and VCAM-1 in Shear-Resistant T Cell Arrest, Polarization, and Directed Crawling on Blood-Brain Barrier Endothelium. J. Immunol. 2010, 185, 4846–4855. [CrossRef]

149. Wu, M.; Zhang, M.; Yin, X.; Chen, K.; Hu, Z.; Zhou, Q.; Cao, X.; Chen, Z.; Liu, D. The Role of Pathological Tau in Synaptic Dysfunction in Alzheimer’s Diseases. Transl. Neurodegener. 2021, 10, 45. [CrossRef]

150. Selkoe, D.J.; Hardy, J. The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years. EMBO Mol. Med. 2016, 8, 595–608. [CrossRef]

151. Konopacka, A.; Zielińska, M.; Albrecht, J. Ammonia Inhibits the C-Type Natriuretic Peptide-Dependent Cyclic GMP Synthesis and Calcium Accumulation in a Rat Brain Endothelial Cell Line. Neurochem. Int. 2008, 52, 1160–1166. [CrossRef]

152. Fessenden, J.D.; Schacht, J. Cyclic GMP-Dependent Protein Kinase-I in the Guinea Pig Cochlea. Hear. Res. 1999, 131, 63–70. [CrossRef]
180. Pedraza, C.E.; Baltrons, M.A.; Heneka, M.T.; García, A. Interleukin-1β and Lipopolysaccharide Decrease Soluble Guanylyl Cyclase in Brain Cells: NO-Independent Destabilization of Protein and NO-Dependent Decrease of MRNA. J. Neuroimmunol. 2003, 144, 80–90. [CrossRef]

181. Baltrons, M.A.; Pifaré, P.; Ferrer, I.; Carot, J.M.; García, A. Reduced Expression of NO-Sensitive Guanylyl Cyclase in Reactive Astrocytes of Alzheimer Disease, Creutzfeldt-Jakob Disease, and Multiple Sclerosis Brains. Neurol. Dis. 2004, 17, 462–472. [CrossRef]

182. Causevic, M.; Begic, E.; Hadzizedic, S.; Kulaglic, A.; Ramic-Brkic, B.; Begic, Z. SOMA-scan-Based Proteome Measurements of Plasma Brain Natriuretic Peptide are Decreased in Mild Cognitive Impairment and in Alzheimer’s Dementia Patients. PLoS ONE 2019, 14, e0212261. [CrossRef]

183. Rutten, K.; De Vente, J.; Šik, A.; Markerink-Van Ittersum, M.; Prickaerts, J.; Blokland, A. The Selective PDE5 Inhibitor, Sildenafil, Improves Object Memory in Swiss Mice and Increases CGMP Levels in Hippocampal Slices. Behav. Brain Res. 2005, 164, 11–16. [CrossRef]

184. Rutten, K.; Basile, J.L.; Prickaerts, J.; Blokland, A.; Vivian, J.A. Selective PDE Inhibitors Rolipram and Sildenafil Improve Object Retrieval Performance in Adult Cynomolgus Macaques. Psychopharmacology 2008, 196, 643–648. [CrossRef]

185. Prickaerts, J.; Šik, A.; Van Der Staay, F.J.; De Vente, J.; Blokland, A. Dissociative Effects of Acetylcholinesterase Inhibitors and Phosphodiesterase Type 5 Inhibitors on Object Recognition Memory: Acquisition versus Consolidation. Psychopharmacology 2005, 177, 381–390. [CrossRef]

186. Puzzo, D.; Staniszweski, A.; XianDeng, S.; Privitera, L.; Leznik, E.; Liu, S.; Zhang, H.; Feng, Y.; Palmeri, A.; Landry, D.W.; et al. Reduced CGMP Levels in CSF of AD Patients Correlate with Severity of Dementia and Current Depression. Alzheimer’s Res. Ther. 2017, 9, 17. [CrossRef]

187. Duszczyk, M.; Kuszczyk, M.; Guridi, M.; Lazarewicz, J.W.; Sadowski, M.J. In Vivo Hippocampal Microdialysis Reveals Impairment of NMDA Receptor–CGMP Signaling in APPsw and APPps/PS1L166P Alzheimer’s Disease. Mol. Chem. Neuropathol. 1998, 35, 77–95. [CrossRef]

188. Hansson, E.; Björklund, U.; Skiöldbrand, E.; Rönnbäck, L. Anti-Inflammatory Effects Induced by Pharmaceutical Substances on NMDA Receptor–CGMP Signaling in APPsw and APPsw/PS1L166P Alzheimer’s Disease. Brain Res. Bull. 2001, 54, 209–216. [CrossRef]

189. Hesse, R.; Lausser, L.; Gummert, P.; Schmid, F.; Wahler, A.; Schnack, C.; Kroker, K.S.; Otto, M.; Tumani, H.; Kestler, H.A.; et al. Central Effects of Sildenafil (Viagra): Is There an Influence on Psychological Performance? Brain Res. 2001, 909, 46–50. [CrossRef] [PubMed]

190. Schultheiss, D.; Müller, S.V.; Nager, W.; Stief, C.G.; Schlotz, N.; Jonas, U.; Asvestis, C.; Johannes, S.; Münte, T.F. Central Effects of Sildenafil (Viagra) on Auditory Selective Attention and Verbal Recognition Memory in Humans: A Study with Event-Related Brain Potentials. World J. Urol. 2001, 19, 46–50. [CrossRef] [PubMed]

191. Fang, J.; Zhang, P.; Zhou, Y.; Li, Y.; Ravi, H.; Peng, S.L.; Diaz-Arrastia, R.; Devous, M.D.; Womack, K.B. Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer’s Disease. J. Alzheimers Dis. 2017, 60, 1351–1364. [CrossRef]
202. Samudra, N.; Motes, M.; Lu, H.; Sheng, M.; Diaz-Arrastia, R.; Devous, M.; Hart, J.; Womack, K.B. A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer’s Disease. *J. Alzheimers Dis.* 2019, 70, 163–170. [CrossRef]

203. Thomas Forgue, S.; Patterson, B.E.; Bedding, A.W.; Payne, C.D.; Phillips, D.L.; Wrishko, R.E.; Mitchell, M.I. Tadalafil Pharmacokinetics in Healthy Subjects. *Br. J. Clin. Pharmacol.* 2005, 61, 280–288. [CrossRef]

204. García-Barroso, C.; Ricobara, A.; Pastas-Lucas, M.; Unceta, N.; Rico, A.J.; Goicoeia, M.A.; Sallés, J.; Lanciego, J.L.; Oyarzabal, J.; Franco, R.; et al. Tadalafil Crosses the Blood–Brain Barrier and Reverses Cognitive Dysfunction in a Mouse Model of AD. *Neuropharmacology* 2013, 64, 114–123. [CrossRef]

205. Salem, M.A.; Budzynska, B.; Kowalczyk, J.; El Sayed, N.S.; Mansour, S.M. Tadalafil and Bergapten Mitigate Streptozotocin-Induced Sporadic Alzheimer’s Disease in Mice via Modulating Neuroinflamm., PI3K/Akt, Wnt/β-Catenin, AMPK/MTOR Signaling Pathways. *Toxicol. Appl. Pharmacol.* 2021, 429, 115697. [CrossRef]

206. Daily, K.P.; Amer, A. Microglial Autophagy-Mediated Clearance of Amyloid-Beta Plaques Is Dysfunctional in Alzheimer’s Disease Mice. *Alzheimer’s Dement.* 2020, 16, e044120. [CrossRef]

207. Nixon, R.A.; Wegiel, J.; Kumar, A.; Yu, W.H.; Peterhoff, C.; Cataldo, A.; Cuervo, A.M. Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study. *J. Neuropathol. Exp. Neurol.* 2005, 64, 113–122. [CrossRef]

208. Orhan, I.E.; Rauf, A.; Saleem, M.; Khalil, A.A. Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/Phosphodiesterases (PDEs). *Curr. Top. Med. Chem.* 2021, 22, 209–228. [CrossRef]

209. Liu, S.; Li, X.; Gao, J.; Liu, Y.; Shi, J.; Gong, Q. Icariside II, a Phosphodiesterase-5 Inhibitor, Attenuates Beta-Amyloid-Induced Cognitive Deficits via BDNF/TrkB/CREB Signaling. *Cell. Physiol. Biochem.* 2018, 49, 1010–1025. [CrossRef]

210. Jin, F.; Gong, Q.-H.; Xu, Y.-S.; Wang, L.-N.; Jin, H.; Li, F.; Li, L.-S.; Ma, Y.-M.; Shi, J.-S. Icariin, a Phosphodiesterase-5 Inhibitor, Improves Learning and Memory in APP/PS1 Transgenic Mice by Stimulation of NO/CGMP Signalling. *Int. J. Neuropsychopharmacol.* 2014, 17, 871–881. [CrossRef]

211. Correia, S.S.; Iyengar, R.R.; Germano, P.; Tang, K.; Bernier, S.G.; Schwartzkopf, C.D.; Tobin, J.; Lee, T.W.H.; Liu, G.; Jacobson, S.; et al. The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals Its Therapeutic Potential in Neurodegenerative Diseases. *Front. Pharmacol.* 2021, 12, 656561. [CrossRef] [PubMed]

212. Russwurm, M.; Mullershausen, F.; Friebe, A.; Jäger, R.; Russwurm, C.; Koesling, D. Design of Fluorescence Resonance Energy Transfer (FRET)-Based CGMP Indicators: A Systematic Approach. *Biochem. J.* 2007, 407, 69–77. [CrossRef] [PubMed]

213. Betolngar, D.B.; Mota, É.; Fabritius, A.; Nielsen, J.; Hougaard, C.; Christoffersen, C.T.; Yang, J.; Kehler, J.; Griesbeck, O.; Castro, L.R.V.; et al. Phosphodiesterase 1 Bridges Glutamate Inputs with NO-and Dopamine-Induced Cyclic Nucleotide Signals in the Striatum. *Cereb. Cortex* 2019, 29, 5022–5036. [CrossRef] [PubMed]

214. Dana, H.; Sun, Y.; Mohar, B.; Hulse, B.K.; Kerlin, A.M.; Hasseman, J.P.; Tsegaye, G.; Tsang, A.; Wong, A.; Patel, R.; et al. High-Performance Calcium Sensors for Imaging Activity in Neuronal Populations and Microcompartments. *Nat. Methods* 2019, 16, 649–657. [CrossRef]

215. Busche, M.A.; Chen, X.; Henning, H.A.; Reichwald, J.; Staufenbiel, M.; Sakmann, B.; Konnerth, A. Critical Role of Soluble Amyloid-β for Early Hippocampal Hyperactivity in a Mouse Model of Alzheimer’s Disease. *Proc. Natl. Acad. Sci. USA* 2012, 109, 8740–8745. [CrossRef]

216. Grienberger, C.; Rochefort, N.L.; Adelsberger, H.; Henning, H.A.; Hill, D.N.; Reichwald, J.; Staufenbiel, M.; Konnerth, A. Staged Decline of Neuronal Function in Vivo as an Animal Model of Alzheimer’s Disease. *Nat. Commun.* 2012, 3, 774. [CrossRef]

217. O’Brien, J.L.; O’Keefe, K.M.; Laviolette, P.S.; Deluca, A.N.; Blacker, D.; Dickerson, B.C.; Sperling, R.A. Longitudinal FMRI in Elderly Reveals Loss of Hippocampal Activation with Clinical Decline. *Neurology* 2010, 74, 1969. [CrossRef]